Free Trial
→ Your free book is about to disappear (From Profits Run) (Ad)tc pixel
OTCMKTS:CYDY

CytoDyn Q2 2026 Earnings Results & Report

CytoDyn logo
$0.25 +0.01 (+3.64%)
As of 12:05 PM Eastern

CytoDyn reported Q2 2026 earnings on January 9, 2026. The company reported EPS of -$0.02.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

CytoDyn EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CytoDyn Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

CytoDyn's Q2 2027 earnings is estimated for Thursday, January 14, 2027, based on past reporting schedules, with a conference call scheduled on Friday, January 8, 2027 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

CytoDyn's Q2 2026 Quarterly ReportQuarterly Report
(10-Q)

CytoDyn Q2 2026 Earnings FAQ

CytoDyn (OTCMKTS:CYDY) reported earnings of -$0.02 per share for Q2 2026. The report was announced on Friday, January 9, 2026.

CytoDyn's next earnings date is estimated for Thursday, January 14, 2027. MarketBeat tracks confirmed and estimated earnings dates for CytoDyn on the company's earnings history page.

CytoDyn Earnings Headlines

CytoDyn raises $5M in private placement to support leronlimab programs
November 12 at 2:45 PM  |  msn.comhttps://www.msn.com/en-us/news/other/cytodyn-raises-5m-in-private-placement-to-support-leronlimab-programs/ar-AA2hiBak
CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors
November 12 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/12/3401607/19782/en/cytodyn-announces-5-million-private-investment-to-advance-leronlimab-in-colorectal-cancer-and-other-solid-tumors.html
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
November 13 at 1:00 AM  |  Crypto 101 Media (Ad)
CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer
November 10 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/10/3399500/19782/en/cytodyn-and-qlhc-advance-leronlimab-into-two-new-pre-i-spy-studies-in-metastatic-triple-negative-breast-cancer.html
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
October 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/26/3388085/19782/en/cytodyn-presents-updated-leronlimab-data-in-metastatic-colorectal-cancer-at-esmo-congress-2026.html
CytoDyn Announces CEO Transition As Board Appoints Hoffman; Lazaleri Steps Down
October 20, 2026  |  rttnews.comhttps://www.rttnews.com/3700720/cytodyn-announces-ceo-transition-as-board-appoints-hoffman-lazaleri-steps-down.aspx
See More CytoDyn Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CytoDyn? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoDyn and other key companies, straight to your email.

About CytoDyn

CytoDyn (OTCMKTS:CYDY) is a biotechnology company focused on developing leronlimab, an investigational humanized monoclonal antibody that targets the CCR5 receptor. The company is based in Vancouver, Washington.

CytoDyn has studied leronlimab in clinical programs involving HIV and cancer, including research into its potential role in treating certain solid tumors. The company’s research has also explored other conditions in which CCR5 may be involved.

Leronlimab is an investigational product and is not an approved commercial therapy. CytoDyn’s activities center on its development and clinical research rather than the sale of marketed medicines.

View CytoDyn Profile
Earnings Tools